In vivo studies using mouse models of prostate cancer confirmed that addition of Wnt5a reduces tumour burden (prolonged dormancy), while Wnt5a knockdown leads to increased detectable metastatic foci in the bone, which appeared sooner than in wild-type mice [36, 41]. This evidence concerns the gene WNT5A and prostate cancer.